EMI Steering Committee
The EMI Steering Committee meets once a year in October and consists of:
- Director of the EMI: Professor Ian Wilkinson (University of Cambridge)
- Co-directors (Industry Partners): Dr. David Howe (MedImmune), Dr. Ben Challis (AstraZeneca) and Dr. Duncan Richards (GSK)
- University of Cambridge Faculty: Dr. Joseph Cheriyan, Dr. Menna Clatworthy, Professor Sadaf Farooqi, Dr. Ferdia Gallagher, Dr. David Jayne, Professor Duncan Jodrell, Dr. Carmel McEniery, Dr. Kevin O’Shaughnessy and Dr. Frank Waldron-Lynch
- Management of the EMI: Mrs. Ann Enticknap (Graduate and Clinical Academic Training), Dr. Mellone Marchong (Office of Translational Research), Mrs. Elizabeth McIntyre (Graduate and Clinical Academic Training)
Director of the EMI
Professor of Therapeutics, University of Cambridge; Director of Cambridge Clinical Trials Unit, Director of the Office of Translational Research
Prof Wilkinson has a long track record in clinical pharmacology and arterial hemodynamics. His research interest is in clinical/experimental studies designed to understand the mechanisms underlying arteriosclerosis and cardiovascular disease, and to understand the importance of novel biomarkers of arterial function in risk prediction. He directs the Cambridge Clinical Trials Unit and is also a director of the Office of Translational Research in Cambridge. He has considerable experience of translational research, and in forming academic collaborations with Industry.
Co-directors – Industry partners
Senior Director in the Respiratory, Inflammation autoimmunity group at MedImmune
Dr. David Howe has been in his current role since 2014 and has over 12 years’ experience in the pharmaceutical industry working in large pharma and start-up biotechnology companies. His major interest lies in early clinical development of new chemical entities, particularly in the design of clinical studies to understand human pharmacology and demonstrate clinical proof of concept.
Before joining the pharmaceutical industry Dr. Howe trained in obstetrics and gynaecology and was a clinical fellow at the MRC Reproductive Biology Unit in Edinburgh (1992-1995), travelling fellow at the University of Toronto and at the Cornell University (1998-2000) and clinical lecturer with a special interest in maternal-fetal medicine at the University of Glasgow (2001-2004).
Honorary Consultant in Endocrinology at Addenbrooke’s Hospital, Cambridge; Associate Director Physician in the Clinical Discovery Unit of Early Clinical Development, AstraZeneca
Dr. Ben Challis completed his undergraduate training in Biochemistry & Chemistry at the University of Western Ontario. He obtained his PhD at the University of Cambridge, where he also obtained his MB BChir and completed specialist medical training in Internal Medicine & Endocrinology and Diabetes as a NIHR funded Academic Clinical Lecturer. His research has focused on the genetics of metabolic disease, particularly obesity and disorders of glucose metabolism, and more recently, endocrine oncology. He is currently an Honorary Consultant in Endocrinology at Addenbrooke’s Hospital in Cambridge. In September 2016, Ben joined AstraZeneca as Associate Director Physician in the Clinical Discovery Unit of Early Clinical Development where his work includes development of genetic- and biomarker-based strategies for human target validation, drug repurposing and experimental medicine studies.
Medicine development leader for anti-SAP for systemic amyloidosis, Director of GSK’s Clinical Unit Cambridge (CUC)
Duncan Richards trained in medicine at Oxford University and after junior doctor roles in London, he returned to Oxford as Clinical Lecturer in Clinical Pharmacology. His DM thesis research was on a translational model using platelet ion flux to interrogate angiotensin biology and he is the author of the Oxford Handbook of Practical Drug Therapy.
Duncan joined GSK in 2003 and has worked in a number of clinical development roles from first in human to file and launch. Duncan is currently medicine development leader for anti-SAP for systemic amyloidosis having been Head of the Academic Discovery Performance Unit during its early clinical development. Duncan has recently also taken on the role of Director of GSK’s phase 1 and the experimental medicine unit in Cambridge (CUC). Duncan has been a strong advocate for the role of experimental medicine in early drug development and chairs GSK’s Experimental Medicine Forum. Externally he is a member of the MRC/NIHR EME Board and serves on several committees of the British Pharmacological Society.
University of Cambridge Faculty
Consultant Physician & Clinical Pharmacologist at Addenbrooke’s Hospital, Associate Lecturer, University of Cambridge, Director of the Cardiovascular Trials Office, Vice Chair of the Cambridge Research Ethics Committee
Dr. Cheriyan is an active clinical researcher with interests in cardiovascular medicine, particularly vascular function and inflammation, and is uniquely the only MHRA accredited Phase I/II clinical triallist on the Cambridge Biomedical Campus working on early phase experimental medicine studies since 2006. His post combines NHS research within a University Department, in close collaboration with GSK’s only remaining in-house Clinical Unit, where he is seconded as a Senior Clinical Pharmacologist.
University Lecturer in Transplantation Medicine. University of Cambridge; Honorary Consultant Nephrologist at Addenbrooke’s Hospital; Fellow and Director of Studies, Clinical Medicine, Pembroke College; Director of NIH-OxCam PhD Programme
Dr. Menna Clatworthy is a Principal Investigator in the Department of Medicine, University of Cambridge. Her lab is based in the Molecular Immunity Unit, within the new MRC Laboratory of Molecular Biology, Her research focuses on immune regulation, particularly of B cell and antibody function. Her clinical interests are in renal transplantation, particularly using novel immunosuppressants to target humoral immunity. She has also written a number of educational textbooks, including Transplantation at a Glance (Wiley Blackwell 2013).
Professor of Metabolism and Medicine
Professor Farooqi’s group’s aim is to understand the fundamental mechanisms involved in human energy homeostasis and to target these mechanisms for therapeutic benefit in obesity.
They have identified mutations in multiple genes encoding components of the leptin-melanocortin pathway in 10% of patients with severe childhood-onset obesity (n=7000). This work has demonstrated the pivotal role of this pathway in the regulation of human energy homeostasis and in mediating the link between weight and blood pressure.
Ongoing genetic and molecular studies inform their programme of experimental medicine research into the causes of obesity and its complications.
University of Cambridge and CRUK Cambridge Research Institute; Honorary Consultant Radiologist at Addenbrooke’s Hospital; Research Fellow at Gonville and Caius College
Dr. Ferdia Gallagher is a CRUK Clinician Scientist and an Honorary Consultant Radiologist in the Department of Radiology at the University of Cambridge. His main interest is developing new molecular imaging methods to study fundamental biological processes in tumours that can be translated into patient care. These techniques include methods to study tissue structure, function and metabolism using MRI and PET. He sits on the CRUK Clinical Research and New Investigators Committees. Dr. Gallagher also directs the local Academic Research Training Programme in Radiology.
Director of the Vasculitis and Lupus Clinic; Reader in Vasculitis in the School of Clinical Medicine at The University of Cambridge, UK
Dr. David Jayne is a certified nephrologist and an Honorary Consultant Physician at Addenbrooke’s Hospital. He is also a medical advisor to the UK, US, and EU regulatory bodies, patient groups, and professional organisations. He has published more than 300 peer-reviewed journal articles, book chapters, and reviews. He was elected the first President of the European Vasculitis Society in 2011, chairs the UKKRC glomerulonephritis and ARUK autoimmune rheumatic diseases, clinical study groups, and is a member of the ERA-EDTA immunopathology working group. His research includes investigator-initiated international trials and the introduction of newer therapies in vasculitis and SLE with collaborators in five continents. He is Senior Examiner in Medicine for the University Clinical School.
Director of Cambridge Cancer Trials Centre (CCTC); Academic Clinical Lead for Early Phase Clinical Trials; Co-Lead of Cambridge Experimental Cancer Medicine Centre (ECMC); Honorary Consultant in Medical Oncology
Prof Duncan Jodrell is a Senior Group Leader at the CRUK Cambridge Institute, where he leads research on new therapeutic approaches for pancreatic cancer. He is also the Cambridge Experimental Cancer Medicine Centre Lead for Early Phase Trials, the Director of the Cambridge Cancer Trials Centre and an honorary consultant in Medical Oncology. He completed his doctoral thesis at the Institute of Cancer Research, post-doctoral research at the University of Maryland and clinical training at the Royal Marsden Hospital and Beatson Oncology Centre. He moved from Edinburgh to Cambridge, when he was elected to the Chair of Cancer Therapeutics in 2008 and also manages a clinical research team, facilitating patients to access new therapies for cancer.
Fellow and College Lecturer in Physiology, Churchill College
Dr. Carmel McEniery’s research interest lies in the haemodynamic consequences of ageing, with a particular focus on arterial stiffening and central blood pressure. She is also interested in the factors underlying the development of hypertension in young individuals, including the influence of ethnicity.
Dr. McEniery is involved in the Anglo-Cardiff Collaborative Trial, a large, community-based investigation into the influence of ageing on blood pressure and arterial haemodynamics and leads the ENIGMA and ENIGMA-Ethnicity Studies, both large, longitudinal follow-up studies investigating the natural history of blood pressure in young adults.
Honorary Consultant Physician, Cambridge University Hospitals NHS Foundation Trust; Fellow of Gonville and Caius College, University of Cambridge; Training Programme Director, Clinical Pharmacology & Therapeutics (Eastern Deanery)
Dr. Kevin O’Shaughnessy is interested in the molecular genetics of essential hypertension and pre-eclampsia, and the role of salt in hypertension.
The recent focus of his group has been the molecular basis of the rare monogenic hypertension syndrome of pseudohypoaldosteronism type 2 (PHA2 or Gordon’s syndrome).
The group is also involved in several large-scale genotyping projects to identify genetic risk factors for pre-eclampsia (as part of the GOPEC consortium) and arterial stiffness (using the ENIGMA cohort).
Principle Investigator in Medical Genetics; Cambridge Institute for Medical Research, Department of Genetics, Department of Medicine
Frank Waldron-Lynch is a physician scientist with extensive European and US experience in translational and experimental medicine leadership. He has been globally trained to specialist/board standard in endocrinology and internal medicine in Ireland, the UK and the USA. Frank is also an expert in innovative clinical trials of immunotherapies to develop treatments for autoimmune and inflammatory diseases.
Management of the EMI
Mrs. Ann Enticknap
Mellone Marchong received her PhD from the Department of Medical Biophysics at the University of Toronto, Canada before coming to the UK to pursue her research interests. She works as a Translational Research Project Manager in the Office for Translational Research (OTR) where she is project managing various projects and programmes. Before joining the OTR she worked for nine years as a cancer research scientist following which she worked for a number of years as a project manager and coordinator of clinical trials.
Mrs. Elizabeth McIntyre
EMI training and recruitment coordinator.
The OTR supports researchers from CUHP translate their research into practical human health benefits, such as new therapeutics, devices, diagnostics or other interventions. We support researchers in their applications for translational funding, developing and managing translational research projects, developing industrial research collaborations and large strategic industrial initiatives and bids.
GCAT is an office within the School of Clinical Medicine. It manages a range of graduate programmes and supports trainees who are on the clinical academic pathway. They work closely with the Health Education East of England Local Education Training Board (HEEoE LETB) and Cambridge University Hospitals NHS Foundation Trust (CUH) and are available to provide advice and assistance to all trainees, students and clinicians seeking information about clinical academic opportunities at the University of Cambridge.